{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:26:29Z","timestamp":1777681589144,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Objective: Although heparin is the current standard anticoagulant during venoarterial (VA) and venovenous (VV) extracorporeal membrane oxygenation (ECMO), factors including heparin-induced thrombocytopenia, heparin resistance and drug shortages necessitate alternative anticoagulants such as direct thrombin inhibitors. The aim was to characterize dosing, safety, and efficacy of bivalirudin during ECMO support. Methods: This retrospective single-center study included 24 adults on ECMO support who received \u22656\u2009hours of bivalirudin. The primary endpoint was dose to first therapeutic activated partial thromboplastin time (aPTT). Secondary endpoints included evaluating dosing between ECMO modes, incidence of bleeding and thrombotic events, and time in therapeutic range (TTR). Results: The dose at time of first therapeutic aPTT was bivalirudin 0.05 [0.05-0.1]\u2009mg\/kg\/hour. Bivalirudin dosing requirements were lower in VAECMO compared to VV-ECMO patients and were not impacted by continuous venovenous hemofiltration. Time to therapeutic aPTT was 5.5 [2-13] hours for VA-ECMO and 4.5 [2-8.6]\u2009hours for VV-ECMO patients. During any mode of ECMO TTR was 58.3% [39.6-73.1]. Thrombotic events occurred in 3 (13%) patients and major bleeding occurred in 12 (50%) patients. Conclusions: Our findings demonstrated variable bivalirudin dosing requirements based on mode of ECMO and dosing modifications may not be required during CVVH. Factors including mode of ECMO, indication for bivalirudin and concomitant antiplatelet therapy may impact hematologic events. Application of this data can assist with developing a bivalirudin ECMO protocol which provides less variability in initial dosing and TTR.<\/jats:p>","DOI":"10.1177\/00185787231188924","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T08:03:22Z","timestamp":1690445002000},"page":"77-85","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Bivalirudin During Adult Extracorporeal Membrane Oxygenation: A Retrospective Characterization of Dosing, Efficacy and Bleeding"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-8680","authenticated-orcid":false,"given":"Natasha D.","family":"Lopez","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie L.","family":"Seto","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E.","family":"Barra","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel J.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel P.","family":"Rosovsky","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond J.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Dalia","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"bibr1-00185787231188924","doi-asserted-by":"publisher","DOI":"10.5492\/wjccm.v8.i6.87"},{"key":"bibr2-00185787231188924","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.03.29"},{"key":"bibr3-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2014.12.001"},{"key":"bibr4-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001869"},{"key":"bibr5-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1051\/ject\/201143005"},{"key":"bibr6-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13520"},{"key":"bibr7-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044440"},{"key":"bibr8-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004944"},{"key":"bibr9-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1186\/cc10556"},{"key":"bibr10-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001598"},{"key":"bibr11-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0910"},{"key":"bibr12-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02357-4"},{"key":"bibr13-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201311-2023OC"},{"key":"bibr14-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv194"},{"key":"bibr15-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2104091"},{"key":"bibr16-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15048"},{"key":"bibr17-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001652"},{"key":"bibr18-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000000780"},{"key":"bibr19-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1177\/03913988221106225"},{"key":"bibr20-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000000691"},{"key":"bibr21-00185787231188924","first-page":"2093","volume-title":"Principles and Practice of Hospital Medicine","author":"Sylvester KW","year":"2017"},{"key":"bibr22-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.14458"},{"key":"bibr23-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1051\/ject\/201850161"},{"key":"bibr24-00185787231188924","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-016-0172-2"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787231188924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787231188924","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787231188924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:40:22Z","timestamp":1777452022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787231188924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/00185787231188924"],"URL":"https:\/\/doi.org\/10.1177\/00185787231188924","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}